TERMS AND CONDITIONS
These are the terms and conditions for Novo Nordisk A/S (“Novo”)
providing you the selected Compounds. By accepting these terms and
conditions, Novo and you are entering into an agreement covering the
transfer and use of the Compounds (the “Agreement”), subject to you
receiving final email notification that Novo has accepted your
request.
Novo will ship the Compounds to you free of charge, however, you
are responsible for any customs or VAT duties applicable in your country.
The Compounds provided to you under this Agreement will be used
solely by you and your team for the Study Purpose (as described in
your Compound request form). Except to the extent necessary to carry
out the Study Purpose, you shall not analyse, modify, synthesise or
create derivatives of any of the Compounds provided under this
Agreement. You agree not to sell or distribute the Compounds to any
third party.
You agree to use the Compounds in compliance with any and all
applicable laws and regulations. You shall not administer the
Compounds to humans under any circumstances.
You are free to publish the data and study results obtained from
the use of the Compounds. You shall acknowledge Novo and the Novo
Nordisk Compound Sharing in any publication publishing such data and
study results. Please use the following format:
“NNCXXXX-XXXX was provided by Novo Nordisk Compound Sharing”
This Agreement shall not be interpreted as granting you any
right or license under any intellectual property, now or hereafter
owned or controlled by Novo. Any intellectual property generated
by you carrying out the Study Purpose will belong to you.
This Agreement will become effective on the date you receive
final email notification that Novo has accepted your request and
will remain effective until the completion of the study. Novo may
terminate this Agreement in case of your material breach of the
Agreement. All terms that are intended to survive termination, will
survive, including but not limited to the Compounds only being used
for the Study Purpose and you acknowledging Novo and the Novo
Nordisk Compound Sharing in any publication.
You cannot assign this Agreement to a third party without the
prior written consent of Novo. Novo will have the right at any time
to assign or transfer any or all of its rights and obligations under
this Agreement to any of its affiliates.
You acknowledge that the Compounds are provided “as is” and
without any representation or warranty, express or implied, as to
the accuracy or completeness of the Compounds, including, without
limitation, any implied warranty of merchantability or fitness for a
particular purpose, or any warranty that the use of the Compounds
will not infringe or violate any patent or other proprietary rights
of any third party. Acceptance of receipt of the Compounds will
constitute acceptance by you of liability for any damages or
injuries resulting from your use of the Compounds.
You and Novo each hereby agrees to hold harmless and indemnify
the other party against any and all losses and/or liabilities
resulting from such party’s breach of this Agreement and/or
unauthorised use and/or disclosure of the Compounds.
THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF DENMARK TO THE EXCLUSION OF ANY RULE THAT WOULD
REFER THE SUBJECT MATTER TO ANOTHER FORUM. YOU AND NOVO AGREE TO THE
EXCLUSIVE JURISDICTION OF THE DANISH COURTS.
NOVO NORDISK PRINCIPLES ON THE USE OF ANIMALS
When performing in vivo experiments, you must adhere to
the following principles:
- All activities involving animals must be conducted strictly in
accordance with present legislation.
- Animals will be used only where no available and acceptable
alternatives exist.
- Alternatives to animal experiments must be used whenever possible.
- Transgenic animals may be used for testing and experiments
when this model is justified.
- Animals bred specifically for experimental purposes must be
used unless special conditions are in evidence.
- Housing, husbandry and transportation of animals must as a
minimum comply with internationally approved standards.
- Housing conditions must take into consideration the special
needs for the animal species in question.
- Housing, husbandry and care of animals must be undertaken by
personnel having received adequate and relevant education. The level
of education must be documented.
- Health control should be supervised by a veterinary officer
experienced in regard to laboratory animals.
- Transportation of animals must be as lenient as possible,
taking into consideration the special needs for the animal species
in question.
- All precautions must be taken to reduce suffering and distress.
- Procedures for monitoring and evaluation of the well-being of
the animals as well as treatment must be implemented.
If you are receiving NNC0100-0454 (insulin degludec),
NNC0090-1170 (liraglutide) or NNC0113-0217 (semaglutide) for
performing in vivo experiments, there is a process for
handling and reporting of potentially serious and unexpected adverse
findings which all personnel supporting the studies must follow.
This is to assure compliance with regulatory requirements. You
will receive a list of ‘expected adverse findings’ which should not
be reported. If there is a finding during your studies that is
determined as potentially serious and unexpected, an email must
immediately be sent to compoundsharing@novonordisk.com with a description
of the finding.
TERMS AND CONDITIONS
These are the terms and conditions for Novo Nordisk A/S (“Novo”)
providing you the selected Compounds. By accepting these terms and
conditions, Novo and you are entering into an agreement covering the
transfer and use of the Compounds (the “Agreement”), subject to you
receiving final email notification that Novo has accepted your request.
Novo will ship the Compounds to you free of charge, however, you
are responsible for any customs or VAT duties applicable in your country.
The Compounds provided to you under this Agreement will be used
solely by you and your team for the Study Purpose (as described in
your Compound request form). Except to the extent necessary to carry
out the Study Purpose, you shall not analyse, modify, synthesise or
create derivatives of any of the Compounds provided under this
Agreement. You agree not to sell or distribute the Compounds to any
third party.
You agree to use the Compounds in compliance with any and all
applicable laws and regulations. You shall not administer the
Compounds to humans under any circumstances.
You are free to publish the data and study results obtained from
the use of the Compounds. You shall acknowledge Novo and the Novo
Nordisk Compound Sharing in any publication publishing such data and
study results. Please use the following format:
“NNCXXXX-XXXX was provided by Novo Nordisk Compound Sharing”
This Agreement shall not be interpreted as granting you any
right or license under any intellectual property, now or hereafter
owned or controlled by Novo. Any intellectual property generated
by you carrying out the Study Purpose will belong to you.
This Agreement will become effective on the date you receive
final email notification that Novo has accepted your request and
will remain effective until the completion of the study. Novo may
terminate this Agreement in case of your material breach of the
Agreement. All terms that are intended to survive termination, will
survive, including but not limited to the Compounds only being used
for the Study Purpose and you acknowledging Novo and the Novo
Nordisk Compound Sharing in any publication.
You cannot assign this Agreement to a third party without the
prior written consent of Novo. Novo will have the right at any time
to assign or transfer any or all of its rights and obligations under
this Agreement to any of its affiliates.
You acknowledge that the Compounds are provided “as is” and
without any representation or warranty, express or implied, as to
the accuracy or completeness of the Compounds, including, without
limitation, any implied warranty of merchantability or fitness for a
particular purpose, or any warranty that the use of the Compounds
will not infringe or violate any patent or other proprietary rights
of any third party. Acceptance of receipt of the Compounds will
constitute acceptance by you of liability for any damages or
injuries resulting from your use of the Compounds.
You and Novo each hereby agrees to hold harmless and indemnify
the other party against any and all losses and/or liabilities
resulting from such party’s breach of this Agreement and/or
unauthorised use and/or disclosure of the Compounds.
THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF DENMARK TO THE EXCLUSION OF ANY RULE THAT WOULD
REFER THE SUBJECT MATTER TO ANOTHER FORUM. YOU AND NOVO AGREE TO THE
EXCLUSIVE JURISDICTION OF THE DANISH COURTS.
TERMS AND CONDITIONS
These are the terms and conditions for Novo Nordisk A/S (“Novo”)
providing you the selected Compounds. By accepting these terms and
conditions, Novo and you are entering into an agreement covering the
transfer and use of the Compounds (the “Agreement”), subject to you
receiving final email notification that Novo has accepted your request.
Novo will ship the Compounds to you free of charge, however, you
are responsible for any customs or VAT duties applicable in your country.
The Compounds provided to you under this Agreement will be used
solely by you and your team for the Study Purpose (as described in
your Compound request form). Except to the extent necessary to carry
out the Study Purpose, you shall not analyse, modify, synthesise or
create derivatives of any of the Compounds provided under this
Agreement. You agree not to sell or distribute the Compounds to any
third party.
You agree to use the Compounds in compliance with any and all
applicable laws and regulations. You shall not administer the
Compounds to humans under any circumstances.
You are free to publish the data and study results obtained from
the use of the Compounds. You shall acknowledge Novo and the Novo
Nordisk Compound Sharing in any publication publishing such data and
study results. Please use the following format:
“NNCXXXX-XXXX was provided by Novo Nordisk Compound Sharing”
This Agreement shall not be interpreted as granting you any
right or license under any intellectual property, now or hereafter
owned or controlled by Novo. Any intellectual property generated
by you carrying out the Study Purpose will belong to you.
This Agreement will become effective on the date you receive
final email notification that Novo has accepted your request and
will remain effective until the completion of the study. Novo may
terminate this Agreement in case of your material breach of the
Agreement. All terms that are intended to survive termination, will
survive, including but not limited to the Compounds only being used
for the Study Purpose and you acknowledging Novo and the Novo
Nordisk Compound Sharing in any publication.
You cannot assign this Agreement to a third party without the
prior written consent of Novo. Novo will have the right at any time
to assign or transfer any or all of its rights and obligations under
this Agreement to any of its affiliates.
You acknowledge that the Compounds are provided “as is” and
without any representation or warranty, express or implied, as to
the accuracy or completeness of the Compounds, including, without
limitation, any implied warranty of merchantability or fitness for a
particular purpose, or any warranty that the use of the Compounds
will not infringe or violate any patent or other proprietary rights
of any third party. Acceptance of receipt of the Compounds will
constitute acceptance by you of liability for any damages or
injuries resulting from your use of the Compounds.
You and Novo each hereby agrees to hold harmless and indemnify
the other party against any and all losses and/or liabilities
resulting from such party’s breach of this Agreement and/or
unauthorised use and/or disclosure of the Compounds.
THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF DENMARK TO THE EXCLUSION OF ANY RULE THAT WOULD
REFER THE SUBJECT MATTER TO ANOTHER FORUM. YOU AND NOVO AGREE TO THE
EXCLUSIVE JURISDICTION OF THE DANISH COURTS.
HUMAN BIOSAMPLES AND INFORMED CONSENT
Definitions. The terms used below shall have the
following meaning.
“Biosamples” means any and all human biological materials
or derivatives, including without limitation, tissue, tissue
derivatives, blood, blood derivative, primary cells, biofluids,
tissue microarrays and isolated cells. Biosamples does not include
materials of a human design derived by synthetic or biomanufacturing
(e.g., antibodies, hormones, cDNA, cell lines).
“Donor” means the person from whom a Biosample is collected.
“Personal Data” means any personal information relating
to a Biosample processed by Recipient as a result of, or in
connection with, carrying out its obligations hereunder, that
relates to an identifiable natural person such as name, initials,
dates of birth, social security number, address, CV information, etc.
“Informed Consent” means the consent for the collection,
storage and use of Biosample(s) from the Donor (or such other person
as may be entitled) that is given in accordance with applicable laws
and exercising that degree of skill, care, diligence, prudence and
foresight which would be reasonably expected from a skilled and
experienced clinical services company. In the event that such
Informed Consent cannot be obtained from a Donor due to
disability/incapacity of that individual, Informed Consent must be
obtained from an individual who is legally authorised to give such
consent on behalf of the incapacitated Donor.
You represent and warrant that (i) in regard to the collection,
storage, handling, transport and testing of Biosamples, you have and
will comply with all applicable laws and regulations and (ii) it is
properly licensed and registered with all applicable regulatory bodies
to perform your obligations under this Agreement in connection with
the use of the Biosamples. You agree to comply with the applicable
laws and regulations relating to the privacy and confidentiality of
patient health information.
You will not send any Personal Data to Novo.
You acknowledge that it is your sole responsibility to, and
represent and warrant to Novo that you will, prior to the collection
and use of any Biosamples, obtain Informed Consent for the collection
and use of the Biosamples to perform the Study Purpose. The Informed
Consent form must appropriately state the risks of obtaining the
Biosample and any conflicts of interest of you. Notwithstanding the
foregoing, in lieu of Informed Consent, you may receive authorisation
to make use of the Biosamples in accordance with this Agreement from a
competent body under applicable law (e.g., IRB or ethics committee (or
equivalent) waiver of consent). You will obtain all other relevant
consents and approvals necessary or desirable to enable use of the
Biosamples in accordance with the terms of this Agreement.
You represent and warrant to Novo that the Donors of the
Biosamples are not paid for providing Informed Consent or
Biosamples. You may reimburse Donor for out-of-pocket costs, loss
of earnings, or other reasonable costs in connection with donating.
For the purposes of ensuring compliance with the
representations, warranties and obligations under this Agreement,
you will keep accurate and detailed books, accounts, and records on
all business activity conducted pursuant to this Agreement. Novo may
at any time request access to relevant consent forms, participation
information etc. (either templates or redacted copies) in order to
ensure compliance.
TERMS AND CONDITIONS
These are the terms and conditions for Novo Nordisk A/S (“Novo”)
providing you the selected Compounds. By accepting these terms and
conditions, Novo and you are entering into an agreement covering the
transfer and use of the Compounds (the “Agreement”), subject to you
receiving final email notification that Novo has accepted your request.
Novo will ship the Compounds to you free of charge, however, you
are responsible for any customs or VAT duties applicable in your country.
The Compounds provided to you under this Agreement will be used
solely by you and your team for the Study Purpose (as described in
your Compound request form). Except to the extent necessary to carry
out the Study Purpose, you shall not analyse, modify, synthesise or
create derivatives of any of the Compounds provided under this
Agreement. You agree not to sell or distribute the Compounds to any
third party.
You agree to use the Compounds in compliance with any and all
applicable laws and regulations. You shall not administer the
Compounds to humans under any circumstances.
You are free to publish the data and study results obtained from
the use of the Compounds. You shall acknowledge Novo and the Novo
Nordisk Compound Sharing in any publication publishing such data and
study results. Please use the following format:
“NNCXXXX-XXXX was provided by Novo Nordisk Compound Sharing”
This Agreement shall not be interpreted as granting you any
right or license under any intellectual property, now or hereafter
owned or controlled by Novo. Any intellectual property generated
by you carrying out the Study Purpose will belong to you.
This Agreement will become effective on the date you receive
final email notification that Novo has accepted your request and
will remain effective until the completion of the study. Novo may
terminate this Agreement in case of your material breach of the
Agreement. All terms that are intended to survive termination, will
survive, including but not limited to the Compounds only being used
for the Study Purpose and you acknowledging Novo and the Novo
Nordisk Compound Sharing in any publication.
You cannot assign this Agreement to a third party without the
prior written consent of Novo. Novo will have the right at any time
to assign or transfer any or all of its rights and obligations under
this Agreement to any of its affiliates.
You acknowledge that the Compounds are provided “as is” and
without any representation or warranty, express or implied, as to
the accuracy or completeness of the Compounds, including, without
limitation, any implied warranty of merchantability or fitness for a
particular purpose, or any warranty that the use of the Compounds
will not infringe or violate any patent or other proprietary rights
of any third party. Acceptance of receipt of the Compounds will
constitute acceptance by you of liability for any damages or
injuries resulting from your use of the Compounds.
You and Novo each hereby agrees to hold harmless and indemnify
the other party against any and all losses and/or liabilities
resulting from such party’s breach of this Agreement and/or
unauthorised use and/or disclosure of the Compounds.
THIS AGREEMENT SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF DENMARK TO THE EXCLUSION OF ANY RULE THAT WOULD
REFER THE SUBJECT MATTER TO ANOTHER FORUM. YOU AND NOVO AGREE TO THE
EXCLUSIVE JURISDICTION OF THE DANISH COURTS.
NOVO NORDISK PRINCIPLES ON THE USE OF ANIMALS
When performing in vivo experiments, you must adhere to
the following principles:
- All activities involving animals must be conducted strictly in
accordance with present legislation.
- Animals will be used only where no available and acceptable
alternatives exist.
- Alternatives to animal experiments must be used whenever possible.
- Transgenic animals may be used for testing and experiments
when this model is justified.
- Animals bred specifically for experimental purposes must be
used unless special conditions are in evidence.
- Housing, husbandry and transportation of animals must as a
minimum comply with internationally approved standards.
- Housing conditions must take into consideration the special
needs for the animal species in question.
- Housing, husbandry and care of animals must be undertaken by
personnel having received adequate and relevant education. The level
of education must be documented.
- Health control should be supervised by a veterinary officer
experienced in regard to laboratory animals.
- Transportation of animals must be as lenient as possible,
taking into consideration the special needs for the animal species
in question.
- All precautions must be taken to reduce suffering and distress.
- Procedures for monitoring and evaluation of the well-being of
the animals as well as treatment must be implemented.
If you are receiving NNC0100-0454 (insulin degludec),
NNC0090-1170 (liraglutide) or NNC0113-0217 (semaglutide) for
performing in vivo experiments, there is a process for
handling and reporting of potentially serious and unexpected adverse
findings which all personnel supporting the studies must follow.
This is to assure compliance with regulatory requirements. You
will receive a list of ‘expected adverse findings’ which should not
be reported. If there is a finding during your studies that is
determined as potentially serious and unexpected, an email must
immediately be sent to compoundsharing@novonordisk.com with
a description of the finding.
HUMAN BIOSAMPLES AND INFORMED CONSENT
Definitions. The terms used below shall have the
following meaning.
“Biosamples” means any and all human biological materials
or derivatives, including without limitation, tissue, tissue
derivatives, blood, blood derivative, primary cells, biofluids,
tissue microarrays and isolated cells. Biosamples does not include
materials of a human design derived by synthetic or biomanufacturing
(e.g., antibodies, hormones, cDNA, cell lines).
“Donor” means the person from whom a Biosample is collected.
“Personal Data” means any personal information relating
to a Biosample processed by Recipient as a result of, or in
connection with, carrying out its obligations hereunder, that
relates to an identifiable natural person such as name, initials,
dates of birth, social security number, address, CV information, etc.
“Informed Consent” means the consent for the collection,
storage and use of Biosample(s) from the Donor (or such other person
as may be entitled) that is given in accordance with applicable laws
and exercising that degree of skill, care, diligence, prudence and
foresight which would be reasonably expected from a skilled and
experienced clinical services company. In the event that such
Informed Consent cannot be obtained from a Donor due to
disability/incapacity of that individual, Informed Consent must be
obtained from an individual who is legally authorised to give such
consent on behalf of the incapacitated Donor.
You represent and warrant that (i) in regard to the collection,
storage, handling, transport and testing of Biosamples, you have and
will comply with all applicable laws and regulations and (ii) it is
properly licensed and registered with all applicable regulatory bodies
to perform your obligations under this Agreement in connection with
the use of the Biosamples. You agree to comply with the applicable
laws and regulations relating to the privacy and confidentiality of
patient health information.
You will not send any Personal Data to Novo.
You acknowledge that it is your sole responsibility to, and
represent and warrant to Novo that you will, prior to the collection
and use of any Biosamples, obtain Informed Consent for the collection
and use of the Biosamples to perform the Study Purpose. The Informed
Consent form must appropriately state the risks of obtaining the
Biosample and any conflicts of interest of you. Notwithstanding the
foregoing, in lieu of Informed Consent, you may receive authorisation
to make use of the Biosamples in accordance with this Agreement from a
competent body under applicable law (e.g., IRB or ethics committee (or
equivalent) waiver of consent). You will obtain all other relevant
consents and approvals necessary or desirable to enable use of the
Biosamples in accordance with the terms of this Agreement.
You represent and warrant to Novo that the Donors of the
Biosamples are not paid for providing Informed Consent or
Biosamples. You may reimburse Donor for out-of-pocket costs, loss
of earnings, or other reasonable costs in connection with donating.
For the purposes of ensuring compliance with the
representations, warranties and obligations under this Agreement,
you will keep accurate and detailed books, accounts, and records on
all business activity conducted pursuant to this Agreement. Novo may
at any time request access to relevant consent forms, participation
information etc. (either templates or redacted copies) in order to
ensure compliance.